Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more
Theravance Biopharma Inc (TBPH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.028x
Based on the latest financial reports, Theravance Biopharma Inc (TBPH) has a cash flow conversion efficiency ratio of -0.028x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.51 Million) by net assets ($232.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Theravance Biopharma Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Theravance Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Theravance Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theravance Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Lyric Robot Automation Co Ltd
SHG:688499
|
0.165x |
|
Cembre S.p.A.
F:J0L
|
0.106x |
|
Shoei Co Ltd
PINK:SHOFF
|
0.027x |
|
STEF S.A
LSE:0NY3
|
0.097x |
|
China Aviation Oil (Singapore) Corporation Ltd
F:VZ8
|
0.107x |
|
POTBELLY - Frankfurt Stock Exchang
F:PTB
|
0.225x |
|
Fulgent Genetics Inc
NASDAQ:FLGT
|
0.010x |
|
YIFILASER ORD A (SHH) EQSW Exp:
SHG:688646
|
N/A |
Annual Cash Flow Conversion Efficiency for Theravance Biopharma Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Theravance Biopharma Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $175.54 Million | $-11.54 Million | -0.066x | +48.16% |
| 2023-12-31 | $213.00 Million | $-27.00 Million | -0.127x | +70.05% |
| 2022-12-31 | $441.80 Million | $-186.99 Million | -0.423x | -168.94% |
| 2021-12-31 | $-338.57 Million | $-207.86 Million | 0.614x | -25.53% |
| 2020-12-31 | $-303.75 Million | $-250.40 Million | 0.824x | -22.53% |
| 2019-12-31 | $-223.84 Million | $-238.20 Million | 1.064x | -51.36% |
| 2018-12-31 | $-51.59 Million | $-112.87 Million | 2.188x | +225.33% |
| 2017-12-31 | $115.18 Million | $-201.05 Million | -1.746x | -517.60% |
| 2016-12-31 | $350.23 Million | $-98.99 Million | -0.283x | +59.31% |
| 2015-12-31 | $243.06 Million | $-168.86 Million | -0.695x | -14.94% |
| 2014-12-31 | $289.79 Million | $-175.16 Million | -0.604x | -108.51% |
| 2013-12-31 | $-17.04 Million | $-120.96 Million | 7.101x | -89.81% |
| 2012-12-31 | $-1.71 Million | $-119.11 Million | 69.653x | +11648.91% |
| 2011-12-31 | $-140.72 Million | $-83.43 Million | 0.593x | -- |